First Trimester Screening for Preeclampsia and Intrauterine Growth RestrIction Using Three Dimensional Doppler Angiography

Pre-Eclampsia Clinical Trial

— SPIRIT  

Official title:

First Trimester Screening for Preeclampsia and Intrauterine Growth RestrIction Using Three Dimensional Doppler Angiography (SPIRIT): A Prospective Study in Nulliparous Pregnant Women

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03342014
• Other study ID #: 2017-A02418-45
• Status: Completed
• Phase: N/A
• Start date: April 16, 2018
• Est. completion date: November 14, 2022

Study information

• Verified date: December 2022
• Source: Central Hospital, Nancy, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Introduction: Preeclampsia (PE) and intrauterine growth restriction (IUGR) are two major pregnancy complications, related to a chronic utero-placental hypoperfusion. Nowadays, there isn't a screening or diagnostic test in clinic for utero-placental vascularization deficiency. Since 2004, 3D Power Doppler angiography has been used for the evaluation of utero-placental vascularisation and three vascular indices have been calculated: the vascularisation index (VI), flow index (FI) and vascularisation-FI (VFI). A high intra and inter-observer reproducibility and its potential interest for placental function study were reported. The investigator's main hypothesis is that these 3DPD indices could provide predictive values for PE and/or IUGR occurrence much higher than those observed with the currents other markers. Objectives: The main objective of this study is to determine differences in 3DPD indices at first trimester between pregnancies defined at their outcome as uncomplicated pregnancy, PE (mild and severe) and IUGR in nulliparous women. Methods and analysis: This is a prospective study. The investigators expect to include 2200 women in 4 French centers: Centre Hospitalier Universitaire de Nancy, Paris-Port-Royal (Assistance Publique - Hôpitaux de Paris), Strasbourg and Belfort (Hôpital Nord Franche-Comté). The nulliparous pregnant women will be recruited during their 1st trimester consultation for routine Down syndrome screening (11-13+6 gestation weeks). Especially for the study, the 3DPD and Uterine Artery Doppler (UAD) acquisition, which last less than 10 min, will be included in the current routine 11-13+6 gestation weeks ultrasound screening. Also, additional blood samples will be taken for biomarker analysis (PAPP-A and P1GF) and biological collection. Utero-placental vascularization indices (VI, FI, VFI) will be quantified using VOCAL® software. For each subgroup (uncomplicated pregnancy, PE and IUGR) mean values in 3DPD indices will be computed and compared using a pairwise t test with a Bonferroni correction p value adjustment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2159
• Est. completion date: November 14, 2022
• Est. primary completion date: November 14, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Singleton nulliparous pregnant women between 11 and 13+6 gestation weeks.
• Mandatory enrolment in a social security plan,
• Patient (or a third person, independent from the investigator and the sponsor, in case of inability to read or write) having signed an informed consent.

Exclusion Criteria:

• Patients under a measure of legal protection.
• Patient under 18,
• Absence of social insurance,
• Patient participating simultaneously to other interventional research trial to test a pharmaceutical treatment and protocols are not compatible,
• Inability to understand and accept the protocol.

Related Conditions & MeSH terms

• Eclampsia
• Fetal Growth Retardation
• Pre-Eclampsia

Intervention

Device:
• Ultrasound
3DPD and UAD acquisitions (10 min)

Biological:
• Blood sample collection
A blood sampling (20 mL) is collected for biomarker analysis (PAPP-A and PlGF) and biological collection.

Locations

Country	Name	City	State
France	Centre Hospitalier Régional Universitaire de Nancy	Vandoeuvre-lès-Nancy

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measure of 3D power Doppler indice : the vascularization index (VI)		through study completion, an average of 40 months
Primary	Measure of 3D power Doppler indice : the flow index (FI)		through study completion, an average of 40 months
Primary	Measure of 3D power Doppler indice : the vascularization-flow index (VFI)		through study completion, an average of 40 months